The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 28, 2025

Filed:

Jul. 26, 2019
Applicant:

Alaya.bio Inc., Cambridge, MA (US);

Inventors:

Anna Miodek, Orsay, FR;

Frédéric Mourlane, Nice, FR;

Cécile Bauche, Paris, FR;

Renaud Vaillant, Gentilly, FR;

Philippe Bishop, Las Vegas, NV (US);

Assignee:

Alaya.bio Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/115 (2010.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
C12N 15/115 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464406 (2023.05); A61K 39/464412 (2023.05); A61K 39/464413 (2023.05); A61K 39/464424 (2023.05); A61K 39/464495 (2023.05); C07K 14/4748 (2013.01); C07K 14/7051 (2013.01); C12N 5/0636 (2013.01); C07K 2319/03 (2013.01); C12N 2310/16 (2013.01); C12N 2310/318 (2013.01); C12N 2310/3519 (2013.01); C12N 2310/51 (2013.01); C12N 2320/13 (2013.01);
Abstract

An aptamer-based switch technology is provided that enhances control of the use of chimeric antigen receptor (CAR)-related immunotherapies. The aptamer-based switch utilizes a synthetic bridge molecule containing a target-binding aptamer bound through a linker to a CAR-binding aptamer. A system containing a CAR and a corresponding aptameric bridge provides an immunotherapy platform that: (i) can be targeted to any desired antigen by choosing the target-binding aptamer of the bridge. (ii) can be redirected from one target to another by changing the target-binding aptamer: (iii) can be dosed according to the changing needs of an individual patient overtime by altering the administration protocol for the bridge: (iv) can be switched on or off quickly or gradually: (v) can be used as a companion diagnostic for a specific CAR therapy: (vi) can be integrated with either in vivo or ex vivo CAR expression: (vii) is non-immunogenic; and (viii) has low production costs.


Find Patent Forward Citations

Loading…